Company news

Akebia Therapeutics, Inc. news in 2023

Akebia Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

November 19, 2023

Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 7, 2023

Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors

November 1, 2023

Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights

October 30, 2023

Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

October 24, 2023

Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023

October 17, 2023

Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat

September 27, 2023

Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update

September 25, 2023

Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference

September 5, 2023

Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 24, 2023

Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023

August 23, 2023

Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights

August 22, 2023

Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023

August 16, 2023

Akebia Therapeutics Provides Update on Form 10-Q Filing

August 9, 2023

Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference

July 18, 2023

Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023

July 17, 2023

Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients

June 28, 2023

Akebia Announces Swissmedic Approval of Vafseo® (vadadustat)

June 19, 2023

Akebia Therapeutics Announces New Chief Financial Officer

June 12, 2023

Akebia Therapeutics to Present at Jefferies Healthcare Conference

June 1, 2023

FDA Provides Akebia Therapeutics a Path Forward for Vadadustat

May 29, 2023

Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia

May 24, 2023

Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 21, 2023

Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

May 21, 2023

Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 7, 2023

Akebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights

April 30, 2023

Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

April 24, 2023

Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split

April 13, 2023

Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders

April 10, 2023

Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023

April 6, 2023

Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study

April 2, 2023

Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat

March 29, 2023

Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting

March 23, 2023

Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

March 8, 2023

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights

March 1, 2023

Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

February 22, 2023

Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

February 20, 2023

Calls in 2023

Decks in 2023